^
    3d
    Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors (clinicaltrials.gov)
    P1, N=75, Suspended, Dana-Farber Cancer Institute | Trial completion date: Jan 2026 --> Jan 2027 | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • gedatolisib (PF-05212384)
    3d
    MOSES: Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Royal Marsden NHS Foundation Trust | Trial completion date: Dec 2028 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2029
    Trial completion date • Trial primary completion date
    4d
    BeeHive: A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University Health Network, Toronto
    New P2 trial • IO biomarker
    |
    Jemperli (dostarlimab-gxly) • risvutatug rezetecan (GSK5764227)
    4d
    Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Institute of Oncology Ljubljana
    New trial • Liquid biopsy • Tumor mutational burden
    5d
    Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=184, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • docetaxel • Tevimbra (tislelizumab-jsgr)
    5d
    Mus musculus papillomavirus MmuPV1 resists restriction by human APOBEC3B. (PubMed, J Virol)
    Surprisingly, we find that human A3B is incapable of blocking the replication of a murine papillomavirus (Mus musculus papillomavirus 1, MmuPV1) in relevant primary cells from these animals or in infected tissues in vivo. These findings highlight the complexity of teasing apart host-pathogen interactions and suggest that papillomaviruses may have a general mechanism for escaping restriction by antiviral enzymes, such as A3B.
    Journal
    |
    APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
    6d
    H101 Plus TACE for r/m HNSCC (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Oncorine (recombinant human adenovirus type 5)
    6d
    A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (clinicaltrials.gov)
    P1/2, N=20, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Apr 2025 | Trial primary completion date: Oct 2026 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Versamune HPV
    6d
    Differentiation grade and combined positive score correlation in head and neck squamous cell carcinoma. (PubMed, World J Surg Oncol)
    However, in hypopharyngeal cancer, the CPS < 20 group exhibited a hazard ratio (HR) for death of 4.55 (95% CI: 1.019-20.31), suggesting a potential clinically relevant difference.This study highlights significant heterogeneity in the immune microenvironment across different subsites of head and neck squamous cell carcinoma. The relationship between CPS and tumor differentiation is site-specific, indicating that the value of CPS as a biomarker for immunotherapy response should be interpreted in the context of tumor location.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    10d
    Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • Loqtorzi (toripalimab-tpzi)
    10d
    Prevalence and Clinical Implications of HPV Infection in Oral Cavity and Oropharynx in HIV+ Men. (PubMed, Int J Dent)
    The prevalence of HPV infection in the oral cavity and oropharynx in HIV + MSM was high; however, the associated OLs were infrequent and not malignant. Future studies are necessary to evaluate the clinical relevance of HPV infection and p16-positive OLs.
    Journal
    |
    CD4 (CD4 Molecule)
    13d
    Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia (clinicaltrials.gov)
    P2, N=98, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open